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Systemic juvenile idiopathic arthritis (sJIA), formerly called Still’s disease, is oﬃcially classiﬁed as a subset of juvenile idiopathic
arthritis (JIA). Beside arthritis, it is characterized by prominent systemic features and a marked inﬂammatory response. Even if it
is still included in the group of juvenile arthritides, sJIA is set apart from all the other forms of JIA. This disorder has markedly
distinct clinical and laboratory features suggesting a diﬀerent pathogenesis. sJIA does not show any association with HLA genes
or with autoantibodies and is characterised by an uncontrolled activation of phagocytes with hypersecretion of IL-1 and IL-6.
Based on clinical and laboratory features, as well as on new acquisitions on the pathogenesis, it seems evident that sJIA is an
autoinﬂammatory disease related to abnormality in innate immune system. The new insights on the pathogenesis of sJIA have
therefore dramatically changed the approach to treatment, with the development of targeted treatments (anti-IL-1 and anti-IL-6
agents) more eﬀective and safer than earlier medications.
1.Introduction
Juvenile idiopathic arthritis (JIA) is the most common
chronicrheumaticdiseaseofchildhood.Itisaheterogeneous
disease of unknown aetiology encompassing diﬀerent forms
of arthritis, which begins before the age of 16 years and
persists for more than 6 weeks. JIA classiﬁcation [1]i sb a s e d
on the number of joints involved during the ﬁrst 6 months of
disease and on the extra-articular involvement.
Most JIA subsets are characterized by female predom-
inance, prominent arthritis, various degrees of biological
inﬂammation, a strong susceptibility associated with some
HLA class II antigens, and an overt or suspected autoimmu-
nity, for example, antinuclear antibodies (ANA) rheumatoid
factor (RF) and anticyclic-citrullinated peptide (anti-CCP)
antibodies. Dramatic response to anti-TNFα treatments [2]
is an important feature, which supports the role of the
adaptative immunity in generating chronic inﬂammation.
2.Still’sDiseaseasaSubsetof
JuvenileIdiopathic Arthritis
sJIA was oﬃcially classiﬁed as a subset of JIA, and the pres-
ence of at least one active synovitis was mandatory to
support the diagnosis, even if some patients do not present
arthritisatdiseaseonset[3].Moreover,sJIAcanhaveahighly
variable outcome, and a monocyclic course with minimal or
absent articular complications was reported in about 50%
of 56 cases [4]. Other diﬀerences with the other subtypes
of JIA include an equal sex ratio, marked systemic features
with spiking fever, a salmon-colored evanescent rash that
comes and goes with fever, serositis, and the absence of
autoantibodies.
The recognition of a group of rare diseases, the autoin-
ﬂammatory diseases (AIDs) appearing to be primarily in-
ﬂammatory in nature because of their periodicity, strong
associations with exogenous triggering events, and lack of
associations with class II MHC haplotypes, brought some
evidence to look at sJIA as a distinct entity from other
subtypes of JIA. Recent advances in understanding the role
of IL-1 in the pathogenesis of sJIA brought strong arguments
to consider the disease as autoinﬂammatory rather than
autoimmune.
3.sJIA asAutoinﬂammatory Disease(AID)
AIDs are a large group of diseases aﬀecting primarily the
innate immune system. Despite their different molecular2 International Journal of Inﬂammation
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Figure 1: Main eﬀects of IL-1. (1) The action on the hypothalamic-pituitary axis inﬂuences the production of the following hormones:
adrenocorticotropic hormone (ACTH), growth hormone (GH), vasopressin or antidiuretic hormone (ADH), and somatostatin. IL-1 is
responsible for the constitutional symptoms in IL-1-dependent diseases (fever, fatigue, anorexia, and growth delay). (2) Liver synthesis and
secretionofacutephaseproteins(bothbydirectIL-1actionandviaIL-6induction).(3)Osteoclastsactivationandmatrixmetalloproteinases
(MMPs) synthesis by chondrocytes, resulting in bone resorption and cartilage degradation, respectively. (4) Innate immune system cells
activation and proliferation, enhanced gene transcription of proinﬂammatory molecules (inducible nitric oxide synthase (iNOS), cyclo-
oxygenase 2 (COX2), and phospholipase A2), proinﬂammatory cytokines, adhesion molecules, and colony-stimulating factors (CSF).
mechanisms, they are all characterized by an inappropriate
activation of the phagocytes, the key cells of innate immune
system. They have in common an overproduction of IL-1β,
a prototype of proinﬂammatory cytokine having pleiotropic
properties (Figure 1). Typical clinical manifestations of AIDs
are recurrent, seemingly unprovoked, inﬂammatory attacks
of fever with skin involvement, serositis, and arthritis. Labo-
ratory examinations during fever attacks show a prominent
acute inﬂammatory response characterised by a marked
leukocytosis (neutrophilia), increased CRP, and serum amy-
loid protein (SAA). Unlike patients with autoimmune dis-
eases, patients with AID lack high-titers autoantibodies and
antigen-speciﬁc T cells.
Historically,AIDscomprisedraredisordersofMendelian
inheritance like cryopyrin associated periodic syndrome
(CAPS) (autosomal dominant) and familial Mediterranean
fever (autosomal recessive). With time, other diseases, less
rare and of multifactorial inheritance, like pFAPA syndrome
(periodic fever, aphtous, pharyngitis, and adenitis), have
joined the group. AIDs uniquely respond to speciﬁc IL-
1β blockade unlike autoimmune diseases that respond dra-
matically to anti-TNFα treatments. Over the past decade, a
growing number of systemic inﬂammatory disorders have
been placed into the group of AIDs given their response
to anti-IL-1 drugs, including sJIA and adult Still’s disease
(AoSD) [5].
4.ClinicalCharacteristicsofsJIA
sJIA represents 10–15% of all JIA, with a broad peak of onset
between 0 and 5 years of age, with 2 years being the most
common [3], and an equal sex ratio. It is called Still’s disease
(AoSD) when it occurs in patients over the age of 16. AoSD is
less common than sJIA but the disease features are the same,
evenseverearthritisoccursexceptionally.Therefore,sJIAand
AoSD likely represent a continuum of the same disease entity
[6].
SJIA is deﬁned by [1] the presence of arthritis in one or
more joints associated with spiking fever (a typically daily
high fever with spike in the evening) persisting for a mini-
mum of 15 days, with at least one of the following manifesta-
tions:skinrash(evanescent,nonﬁxederythematousrashthat
accompanies fever spikes), generalized lymphadenopathy,
hepatomegaly and/or splenomegaly, or serositis (pleuritis or
pericarditis).
None of the clinical signs is speciﬁc to sJIA, especially at
presentation, and diﬀerential diagnosis can be diﬃcult (bac-
terial and viral infections, malignancy, and other rheumatic
diseases). Moreover, arthritis may be absent at onset and
can develop during disease course, usually progressing to a
polyarticular and symmetrical involvement.
The disease course can be highly variable. It can be
monocyclic, polycyclic with relapses followed by intervals of
remission, or unremitting, leading about half of the patients
toachronicdestructivearthritisrepresentingthemajorlong-
term problem.
SJIA shows a strong association with macrophage activa-
tion syndrome (MAS), a form of reactive hemophagocytic
lymphohistiocytosis (HLH), characterised by an uncon-
trolled activation of well-diﬀerentiated macrophages releas-
ing a high amount of proinﬂammatory cytokines, partic-
ularly IL-18, which belongs to the IL-1 family. MAS isInternational Journal of Inﬂammation 3
a severe, potentially life-threatening disorder, and clinically
characterized by fever, hepatosplenomegaly, lymphadenopa-
thy, neurologic dysfunction, and coagulopathy. Some studies
suggest that up to 50% of sJIA patients might have occult
MAS [7, 8]. Heterozygous mutations in genes involved in
HLH have been described in some subsets of SoJIA patients
andmightplayaroleinthedevelopmentofMAS[9].Speciﬁc
criteria for sJIA-associated MAS have been recently proposed
[10]. Interestingly, MAS has been recently included as an
individualgroupofautoinﬂammatorydiseasesinanupdated
classiﬁcation proposed by Masters et al. [5].
5. Laboratory
Laboratory tests show a marked inﬂammatory response with
leukocytosis (neutrophilia), thrombocytosis, high C-reactive
protein (CRP) and erythrocyte sedimentation rate (ESR).
In most cases a microcytic anaemia related to prominent
inﬂammation is detected.
Markedly distinct clinical and laboratory features of sJIA
suggest a diﬀerent pathogenesis from the other forms of JIA.
OligopolyarticularformofJIA(themostfrequentform)isan
antigen-driven lymphocyte-mediated autoimmune disease
with abnormality in the adaptive immune system [11]. On
the other side, sJIA does not show any association with HLA
genes nor with autoantibodies and is characterised by an
uncontrolled activation of phagocytes. These features are
all consistent with what is observed in autoinﬂammatory
diseases [12–14].
6. Pathogenesis of sJIA
Phagocytes including monocytes, macrophages, and neu-
trophils are the principal activated cells during the early
course of sJIA. It has been shown that these cells secrete very
high levels of pro-inﬂammatory cytokines (IL-1, IL-6, IL-18)
as well as proinﬂammatory proteins (S100A8, S100A9, and
S100A12) [15–17].
7. The Role of IL-1insJIA
The discovery of an important role of IL-1 in the etiopatho-
genesis of sJIA came from studies that analyzed gene tran-
scription patterns in peripheral blood mononuclear cells
(PBMCs) from healthy individuals, incubated with serum
from patients with active disease. Serum from sJIA patients
can induce the transcription of IL-1β and various IL-1-
related genes in healthy PBMCs [12]. Activated monocytes
from sJIA patients secreted higher amounts of IL-1 (16-fold
greater) compared to monocytes from healthy controls. The
role of IL-1 was conﬁrmed by studies showing the eﬃcacy
of anakinra, a recombinant anti-IL-1 receptor antagonist
[12, 18]. Similar results were also reported for the related
disorder AoSD [19].
Several open-label studies reported the clinical eﬃcacy
of anakinra in sJIA patients, with response rates around
50% [12, 19, 20]. More recently, a randomised double-blind
placebo-controlled study in sJIA reported similar clinical
response rates and normalization of the expression of genes
involved in IL-1β regulation [18]. Despite a good short-
term clinical control, most patients experienced loss of
eﬃcacy with ongoing anakinra treatment. The latter might
be due to patients selection, being more likely observed in
patients with long-standing refractory disease or in those
with polyarticular involvement. Accordingly, in a case series
of22pediatricsJIApatients,alowjointcountandhighblood
PMNwerepositivepredictorsofclinicalresponsetoanakinra
[20].
Nigrovic et al. recently reported a retrospective study
with anakinra as ﬁrst-line treatment in sJIA, with 59% of
patients undergoing remission [21]. Early introduction of
anakinra hindered arthritis relapse in 90% of patients. Fur-
ther studies on the eﬃcacy and safety of anakinra as ﬁrst-line
treatment are needed.
The response to anakinra can therefore identify two sub-
sets of sJIA patients, one with dramatic response similar to
that observed in (CAPS) [20, 22] and the other resistant or
with an intermediate response [18, 21].
Preliminary results on canakinumab and rilonacept
treatment showed a high eﬃcacy in sJIA patients [23, 24].
8. The Role of IL-6
The levels of IL-6 are markedly elevated in the serum and
synovial ﬂuid of sJIA compared to other subtypes of JIA.
Circulating levels are increased during the peak of fever
and correlate with clinical activity, systemic features as
thrombocytosis and microcytic anemia, growth retardation,
osteopenia, and the extent and severity of joint involvement
[16, 25, 26]. It has been suggested that polymorphisms
involving the promoter elements and genes encoding IL-6
maycontributetotheoverproductionofIL-6insJIA[27,28].
The major pathogenic role of IL-6 has been conﬁrmed by
the marked eﬃcacy of tocilizumab, a monoclonal antibody
targeting the IL-6 receptor, in reducing systemic features
like fever and rash and improving inﬂammatory arthritis
[29, 30].
9. The Role of IL-18
IL-18isamemberoftheIL-1cytokinesuperfamily,produced
mainly by monocytes macrophages in response to viral or
bacterial stimuli, which may contribute to the inﬂammatory
process. sJIA, AoSD, and MAS are all characterised by
extremely high IL-18 serum levels [31, 32]. Some reports
have recently shown its elevation during sJIA ﬂares and
during the active phase of MAS [31]. A defective phospho-
rylation of IL-18 receptor has been reported in sJIA patients
[33].
Based on clinical and laboratory features as well as on
the new acquisitions on the pathogenesis, it seems evident
that sJIA is an autoinﬂammatory disease related to abnor-
mality in innate immune system. The marked activation
of innate immune system responsible for the multisystem
inﬂammation and the lack of any consistent association
with HLA antigens or autoantibodies allow to consider sJIA4 International Journal of Inﬂammation
as an autoinﬂammatory disease. This hypothesis is further
conﬁrmed by the response to anti-IL-1 and IL-6 agents.
Nevertheless, even if there is evidence for IL-1β deregu-
lation on sJIA, further fundamental experiments are needed
to explain whether this is due to intrinsic abnormalities in
caspase-1 activation or it is rather linked to extrinsic mech-
anisms involving, for example, the TLRs and NF-KB acti-
vation pathway. From a clinical point of view, not every
patient may respond completely to IL-1 inhibition, and the
presence of polyarthritis is associated to worse results. The
development of arthritis could be associated to a cytokine
shift towards IL-6 and TNFα. The response of sJIA to
tocilizumab (anti-IL-6 agent) is not contradictory because
the IL-1β induces downstream secretion of IL-6, which
shares many biological properties with IL-1.
The new acquisitions on the pathogenesis of sJIA have
therefore dramatically changed its management, with the de-
velopment of targeted therapy more eﬀective and safer than
earlier medications.
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